Utility of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19

• Status: Not yet recruiting
• Trial end date: 2020-11-01
• Target enrollment: 0
• Participant gender: All

Summary

COVID 19, which probably started from zoonotic transmission related to crowded markets in China was announced as a pandemic by the WHO on 11 March 2020.

There is currently no clinically proven specific antiviral agents available for SARS-CoV-2 infection. Supportive treatment, including oxygen therapy, fluid management, and broad-spectrum antibiotics to cover secondary bacterial infection, remains the most important management strategy.

Since its discovery, lactoferrin and its related peptides are considered non-specific host defense molecules against a broad range of viruses including SARS-CoV, which is closely related to SARS-CoV-2 that causes COVID-19. Besides reducing viral entry, lactoferrin can also suppress virus replication after the viral entry and has an immunomodulatory effect that can prevent the cytokine storm associated with COVID-19.

The aim of our study is to assess the safety and efficacy of lactoferrin within the context of SARS-CoV-2 and propose the possibility of supplemental lactoferrin as a potential preventive drug for healthcare workers exposed to SARS-CoV-2.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Lactoferrin

Criteria

Inclusion Criteria:

• health care workers at risk of SARS-CoV-2 transmission with no previous diagnosis of SARS-CoV-2 infection

• No symptoms compatible with SARS-CoV-2 (COVID-19) until the date of enrolment in the study.

Exclusion Criteria:

• Known allergy or hypersensitivity to the used medications